RLYB-212

N/A

Report date: 2026/01/14 20:00:44

Base Information

Drug NameRLYB-212
Drug Alias Namerecombinant human IgG monoclonal HPA-1a antibodyRLYB-212RLYB212
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionIntegrin beta-3 inhibitors
TargetsIntegrin beta-3
Therapy Area/IndicationsThrombocytopenia, Neonatal AlloimmuneHematologic Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumSwedenNetherlands +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesProphylix Pharma As
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJohnson & Johnson Innovation - Jjdc IncRallybio IPA LLCRallybio Corp +[4] 
Active IndicationsN/A
Inactive IndicationsThrombocytopenia, Neonatal AlloimmuneHematologic Diseases

Other Information

ATC CodeN/A
Related LinksN/A